MH002 enters phase 2b: Can MRM Health’s live biotherapeutic consortium redefine ulcerative colitis treatment standards?
MRM Health's MH002 enters phase 2b for ulcerative colitis. Can this live biotherapeutic redefine immune-sparing treatment in IBD? Find out what’s at stake.